2002-2021 年挪威西部围手术期和非围手术期患者输血相关过敏性休克。

IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion Pub Date : 2024-11-01 Epub Date: 2024-05-15 DOI:10.2450/BloodTransfus.738
Bjarte Skoe Erikstein, Marie Bjørbak Alnæs, Torunn Oveland Apelseth
{"title":"2002-2021 年挪威西部围手术期和非围手术期患者输血相关过敏性休克。","authors":"Bjarte Skoe Erikstein, Marie Bjørbak Alnæs, Torunn Oveland Apelseth","doi":"10.2450/BloodTransfus.738","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anaphylaxis after blood transfusion is a feared complication accounting for severe morbidity. A retrospective study was performed at Haukeland University Hospital, Bergen, Norway, to investigate the rate and features of transfusion-associated anaphylaxis (TAA) occurring between 2002-2021.</p><p><strong>Materials and methods: </strong>Identified cases of TAA were studied by an immunologist and an allergist to extract information about general characteristics, amplifying factors, co-morbidity, treatment, and treatment responses. TAA was reported as perioperative or non-perioperative.</p><p><strong>Results: </strong>We identified 29 cases of TAA: 13 perioperative and 16 non-perioperative. Allergic transfusion reaction had an incidence rate of 34/100,000 transfusions and TAA a rate of 7/100,000 transfusions. The incidence of allergic reactions and TAA increased 2.6- and 6.4-fold during the study period. The first perioperative TAA was discovered 12 years into the study period but was equally frequent as non-perioperative transfusion-associated anaphylaxis in the last five years of the study period. 52% of the TAA cases had relevant co-morbidity and 100% of them had amplifying factors. Although only 38% of the non-perioperative patients received epinephrine as treatment, 94% of them had a good treatment response to their total treatment regimen. Poorer treatment response was observed with higher age, more cardiovascular- and respiratory disease, higher use of amplifying and sedating medications and a higher severity score.</p><p><strong>Discussion: </strong>Our findings indicate that TAA, especially in the perioperative setting, is underdiagnosed. The increased incidence of TAA in our study is temporally related to the introduction of a national hemovigilance program, introduction of standardized laboratory testing for anaphylaxis and increased multidisciplinary focus on the condition. In conclusion, increased awareness of TAA, and especially in the perioperative setting, is needed. A multidisciplinary approach is necessary to improve identification and reporting of TAA.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"502-513"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576146/pdf/","citationCount":"0","resultStr":"{\"title\":\"Blood transfusion-associated anaphylaxis in perioperative- and non-perioperative patients in Western Norway 2002-2021.\",\"authors\":\"Bjarte Skoe Erikstein, Marie Bjørbak Alnæs, Torunn Oveland Apelseth\",\"doi\":\"10.2450/BloodTransfus.738\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Anaphylaxis after blood transfusion is a feared complication accounting for severe morbidity. A retrospective study was performed at Haukeland University Hospital, Bergen, Norway, to investigate the rate and features of transfusion-associated anaphylaxis (TAA) occurring between 2002-2021.</p><p><strong>Materials and methods: </strong>Identified cases of TAA were studied by an immunologist and an allergist to extract information about general characteristics, amplifying factors, co-morbidity, treatment, and treatment responses. TAA was reported as perioperative or non-perioperative.</p><p><strong>Results: </strong>We identified 29 cases of TAA: 13 perioperative and 16 non-perioperative. Allergic transfusion reaction had an incidence rate of 34/100,000 transfusions and TAA a rate of 7/100,000 transfusions. The incidence of allergic reactions and TAA increased 2.6- and 6.4-fold during the study period. The first perioperative TAA was discovered 12 years into the study period but was equally frequent as non-perioperative transfusion-associated anaphylaxis in the last five years of the study period. 52% of the TAA cases had relevant co-morbidity and 100% of them had amplifying factors. Although only 38% of the non-perioperative patients received epinephrine as treatment, 94% of them had a good treatment response to their total treatment regimen. Poorer treatment response was observed with higher age, more cardiovascular- and respiratory disease, higher use of amplifying and sedating medications and a higher severity score.</p><p><strong>Discussion: </strong>Our findings indicate that TAA, especially in the perioperative setting, is underdiagnosed. The increased incidence of TAA in our study is temporally related to the introduction of a national hemovigilance program, introduction of standardized laboratory testing for anaphylaxis and increased multidisciplinary focus on the condition. In conclusion, increased awareness of TAA, and especially in the perioperative setting, is needed. A multidisciplinary approach is necessary to improve identification and reporting of TAA.</p>\",\"PeriodicalId\":49260,\"journal\":{\"name\":\"Blood Transfusion\",\"volume\":\" \",\"pages\":\"502-513\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576146/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2450/BloodTransfus.738\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2450/BloodTransfus.738","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:输血后过敏性休克是一种可怕的并发症,会导致严重的发病率。挪威卑尔根的豪克兰大学医院开展了一项回顾性研究,调查2002-2021年间发生的输血相关过敏性休克(TAA)的发病率和特征:一名免疫学家和一名过敏学家对确定的 TAA 病例进行了研究,以提取有关一般特征、放大因素、并发症、治疗和治疗反应的信息。TAA 按围手术期或非围手术期报告:结果:我们发现了 29 例 TAA:13 例围手术期,16 例非围手术期。过敏性输血反应的发生率为 34/100,000,TAA 的发生率为 7/100,000。在研究期间,过敏反应和TAA的发生率分别增加了2.6倍和6.4倍。首例围手术期 TAA 是在研究期间的 12 年后发现的,但在研究期间的最后 5 年,其发生率与非围手术期输血相关过敏性休克相同。52% 的 TAA 病例有相关并发症,100% 的病例有扩大因素。虽然只有 38% 的非手术患者接受了肾上腺素治疗,但其中 94% 的患者对其总体治疗方案反应良好。年龄越大、心血管和呼吸系统疾病越多、使用扩容和镇静药物越多以及严重程度评分越高,治疗反应越差:讨论:我们的研究结果表明,TAA,尤其是围手术期的 TAA 诊断不足。在我们的研究中,TAA 发生率的增加与国家血液监测计划的引入、过敏性休克标准化实验室检测的引入以及多学科对该病症关注度的提高有关。总之,需要提高对 TAA 的认识,尤其是在围手术期。有必要采用多学科方法来改进 TAA 的识别和报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Blood transfusion-associated anaphylaxis in perioperative- and non-perioperative patients in Western Norway 2002-2021.

Background: Anaphylaxis after blood transfusion is a feared complication accounting for severe morbidity. A retrospective study was performed at Haukeland University Hospital, Bergen, Norway, to investigate the rate and features of transfusion-associated anaphylaxis (TAA) occurring between 2002-2021.

Materials and methods: Identified cases of TAA were studied by an immunologist and an allergist to extract information about general characteristics, amplifying factors, co-morbidity, treatment, and treatment responses. TAA was reported as perioperative or non-perioperative.

Results: We identified 29 cases of TAA: 13 perioperative and 16 non-perioperative. Allergic transfusion reaction had an incidence rate of 34/100,000 transfusions and TAA a rate of 7/100,000 transfusions. The incidence of allergic reactions and TAA increased 2.6- and 6.4-fold during the study period. The first perioperative TAA was discovered 12 years into the study period but was equally frequent as non-perioperative transfusion-associated anaphylaxis in the last five years of the study period. 52% of the TAA cases had relevant co-morbidity and 100% of them had amplifying factors. Although only 38% of the non-perioperative patients received epinephrine as treatment, 94% of them had a good treatment response to their total treatment regimen. Poorer treatment response was observed with higher age, more cardiovascular- and respiratory disease, higher use of amplifying and sedating medications and a higher severity score.

Discussion: Our findings indicate that TAA, especially in the perioperative setting, is underdiagnosed. The increased incidence of TAA in our study is temporally related to the introduction of a national hemovigilance program, introduction of standardized laboratory testing for anaphylaxis and increased multidisciplinary focus on the condition. In conclusion, increased awareness of TAA, and especially in the perioperative setting, is needed. A multidisciplinary approach is necessary to improve identification and reporting of TAA.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Transfusion
Blood Transfusion HEMATOLOGY-
CiteScore
6.10
自引率
2.70%
发文量
91
审稿时长
2 months
期刊介绍: Blood Transfusion welcomes international submissions of Original Articles, Review Articles, Case Reports and Letters on all the fields related to Transfusion Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信